INTRODUCTION {#S1}
============

Durable protective humoral immunity requires the continual production of antigen (Ag)-specific antibodies (Ab) by terminally differentiated plasma cells (PCs) ([@R7]). Given that the half-life of circulating Ab molecules is days to weeks ([@R17]) while the half-life of Ab titers can be decades in humans ([@R1]), sustained Ab levels directly reflect the maintenance of PC populations producing those Abs. These can be the short-lived PC (SLPC) subset ([@R69]), which is replenished by memory B cells activated upon Ag re-exposure ([@R5]). However, Ab titers can persist without continual Ag availability or B cells ([@R6]; [@R21]; [@R43]), and these are produced by the long-lived PC (LLPC) subset, which can survive for years to decades ([@R57]; [@R69]).

LLPCs are not intrinsically long lived; rather, they are dependent upon access to and interaction with specific niches for their survival. LLPCs reside primarily in the bone marrow (BM) and SLPCs in secondary lymphoid organs such as the spleen (SP), although other sites exist ([@R57]). Stromal niche components that support LLPC survival include eosinophils, basophils, T regulatory cells, dendritic cells (DC), mesenchymal stromal cells, and megakaryocytes ([@R12]; [@R20]; [@R47], [@R48]; [@R50]; [@R60]; [@R77]), as well as soluble factors such as APRIL, BAFF, and IL-6 ([@R4]; [@R47]). There are also PC-intrinsic programs that specifically support LLPC survival, including a distinct and essential metabolic program of high glucose uptake and increased mitochondrial respiratory capacity ([@R35], [@R36]; [@R46]). However, how this metabolic program is regulated, and why this is different from SLPCs, is unknown.

During B cell differentiation, genes necessary for PC survival and function are upregulated, including *Irf4, Prdm1, Xpb1,* and, interestingly, *Cd28* ([@R14]). CD28 is the prototypic T cell costimulatory receptor ([@R23]; [@R29]) that in conjunction with T cell receptor (TCR) augments activated T cell function and survival ([@R26]; [@R38]; [@R39]; [@R67]; [@R76]). Importantly, CD28 co-stimulation enhances T cell metabolic fitness through induction of glycolysis and upregulation of mitochondrial respiration and fatty acid oxidation (FAO) ([@R11]; [@R18]). CD28 co-stimulation is also essential for memory T cell generation through the reorganization of mitochondrial architecture and increased mitochondrial spare respiratory capacity ([@R31]).

Although CD28 is expressed on murine and human PCs (but not on B cells) ([@R25]; [@R33]; [@R61]) and on the BMPC malignancy multiple myeloma (MM) ([@R54]; [@R59]; [@R68]; [@R78]), its function in PCs has been largely uncharacterized. Loss of CD28 in PCs was initially shown to inhibit early Ab responses ([@R14]; [@R64]). We subsequently found that PC-intrinsic CD28 signaling (upon engaging its ligands CD80/CD86 on niche DCs, without a "signal 1" needed by T cells) was required for BM LLPC survival and sustained Ag-specific Ab titers ([@R61], [@R62]). Although SLPCs express CD28, receptor activation did not induce pro-survival signaling seen in LLPCs. However, another study found that B lineage-specific loss of CD28 enhanced the generation of SLPCs, LLPCs, and resulting Ab responses ([@R53]), suggesting additional complexity of CD28's role in PC biology.

The basis for the CD28 signaling differences between LLPCs and SLPCs is unknown but may represent a key determinant as to whether a PC can use the LLPC niche. We therefore sought to understand why CD28 transduces a pro-survival signal specifically in LLPCs and whether this regulates the LLPC metabolic program.

RESULTS {#S2}
=======

SLP76 Is Required for CD28-Mediated LLPC Survival {#S3}
-------------------------------------------------

To understand how CD28 activation promotes LLPC but not SLPC survival, we first characterized the downstream signaling pathways. The CD28 cytoplasmic tail has two binding motifs that direct PI3K (tyrosine 170) or Grb2/Vav signaling (PYAP motif) ([@R9]). We have shown that inactivating mutations in the PYAP motif (CD28-AYAA-knockin \[KI\] mice; [@R9]) significantly diminished LLPC survival and sustained Ag-specific Ab production *in vivo* ([@R62]). In T cells, TCR and CD28 co-activation merge to recruit the adaptor protein SLP76 to the Grb2/Vav complex at the CD28 receptor tail ([@R45]), and this links CD28 co-stimulation to phosphorylation/activation of PLCγ1 ([@R74]). SLP76 is also expressed in B cells ([@R13]; [@R49]; [@R52]; [@R56]; [@R71]), but its role is not well characterized, as SLP65 assumes SLP76's function for B cell receptor signaling ([@R32]). As CD28/Grb2/Vav signaling induced phosphorylation of PLCγ1 in LLPCs but not SLPCs ([@R62]), we examined whether LLPCs and SLPCs had differing SLP76 expression to explain the difference in CD28 signaling.

Initial transcriptomic analysis of human B cell differentiation subsets ([@R72]) demonstrated that *Lcp2* (encoding SLP76) was most highly expressed in BMPCs ([Figure 1A](#F1){ref-type="fig"}). Note that the field has traditionally used BMPCs and LLPCs versus splenic PCs (SPPCs) and SLPCs interchangeably, and we do so throughout this report with the understanding that the subsets are clearly more complex. Consistent with these human data, comparison of *Lcp2* expression in murine splenic B220^+^ B cells, B220^+^CD38^+^ plasmablasts (PBs), and B220^−^CD138^+^ PCs ([@R3]) found highest expression in the PCs ([Figure 1B](#F1){ref-type="fig"}). Analysis of a separate microarray dataset ([@R22]) showed higher *Lcp2* expression in murine BMPCs versus SPPCs ([Figure 1C](#F1){ref-type="fig"}).

Transcriptomic analysis has the caveat that experimental conditions, technical approaches, and subset heterogeneity vary considerably across the available datasets. To directly assess SLP76 protein expression, we performed flow cytometric analysis and found intracellular SLP76 expression in both B220^−^CD138^+^ SPPCs and BMPCs ([Figure 1D](#F1){ref-type="fig"}, upper left), but expression was significantly higher in BMPCs ([Figure 1D](#F1){ref-type="fig"}, upper right). SLP76 expression in BMPCs is less but comparable with CD3^+^ T cells in these same samples ([Figure 1D](#F1){ref-type="fig"}, lower). This is consistent with *Lcp2* RNA expression and suggests a basis for CD28 signaling in LLPCs but not in SLPCs.

To directly assess this, we used SLP76-KI mice that have a disabling Y112/128F mutation in the SLP76 Vav binding domain ([@R28]). Importantly, T cell help in these mice appears largely intact, as evidenced by their ability to clear acute lymphocytic choriomeningitis virus (LCMV) infection equivalently to wild-type (WT) mice ([@R70]). BMPCs and SPPCs were purified from WT and SLP76-KI mice and treated *in vitro* with control versus activating anti-CD28 monoclonal antibody (mAb) in serum-free conditions. CD28 activation protected WT BMPCs from serum starvation-induced death, as previously reported ([@R51]; [@R61], [@R62]) but could not rescue SLP76-KI BMPCs ([Figure 2A](#F2){ref-type="fig"}), and as expected had no effect WT or SLP76-KI SPPC survival ([Figure 2B](#F2){ref-type="fig"}). These findings indicate a LLPC-intrinsic role for SLP76 in CD28-mediated survival.

If SLP76 links the CD28 receptor to downstream Grb2/Vav pro-survival signaling in LLPCs, loss of this linkage would mirror *in vivo* what is seen in the CD28-AYAA mice, in which CD28 is not capable of binding Grb2/Vav. Although WT and SLP76-KI mice had equivalent numbers of T cells from BM and SP ([Figure 2C](#F2){ref-type="fig"}, left), there were significantly fewer BMPCs in the SLP76-KI mice ([Figure 2C](#F2){ref-type="fig"}, right). There was no difference in the number of SPPCs, which also suggests intact T cell help in the SLP76-KI mice. The SLP76-KI mice also had lower percentages of BMPCs in the total mononuclear population, but no difference in the percentage of SPPCs ([Figure 2D](#F2){ref-type="fig"}). The reduced SLP76-KI BMPC population was also reflected in a smaller number of BM IgG-secreting cells ([Figure 2E](#F2){ref-type="fig"}). This selective loss of BM LLPCs in the SLP76-KI *in vivo* mice closely mirrors what is seen in the CD28-AYAA mice ([@R62]). Altogether, these data indicate that CD28's pro-survival signal in LLPCs is dependent on SLP76 expression and suggest that lower SLP76 expression in SLPCs disables this signaling.

CD28 Regulates Glucose Uptake in LLPCs {#S4}
--------------------------------------

In T cells, SLP76 levels regulate the balance between effector and memory CD4 T cells ([@R27]), which have distinct metabolic programs ([@R10]). CD28 co-stimulation similarly regulates T cell metabolism by upregulating expression of the glucose transporter GLUT1 and glucose metabolism in effector T cells ([@R18]) and enhancing mitochondrial respiration in memory T cells ([@R31]). The recent observation that LLPCs have higher glucose uptake than SLPCs ([@R35], [@R36]) led us to examine if CD28 regulated glucose use in LLPC.

Using the fluorescent glucose analog 2-(*N*-\[7-nitrobenz-2-oxa-1,3-diazol-4-yl\]amino)-2-deoxyglucose (NBDG), we confirmed in unvaccinated mice that BMPCs take up more glucose than SPPCs ([Figure 3A](#F3){ref-type="fig"}). To determine a role for CD28 signaling, we first examined if T cells from CD28-AYAA mice have a defect in glucose use, which is unknown but predicted given the reported defects in T cell function ([@R16]). After 24 h of activation, CD28-AYAA T cells had significantly lower rates of glycolysis compared with WT T cells ([Figure 3B](#F3){ref-type="fig"}). Given this defect, we assessed whether CD28-AYAA LLPCs also had diminished glucose uptake. NBDG uptake in freshly isolated CD28-AYAA BMPCs was significantly lower versus WT BMPCs ([Figure 3C](#F3){ref-type="fig"}, left), which was also seen for the CD28-AYAA SPPCs ([Figure 3C](#F3){ref-type="fig"}, right). In contrast, NBDG uptake in the BM B220^+^ B cells ([Figure S1A](#SD1){ref-type="supplementary-material"}) and SP B220^+^ B cells ([Figure S1B](#SD1){ref-type="supplementary-material"}) in these same samples was not different between WT and CD28-AYAA mice, which serves as an important internal technical control. CD28 activation in WT BMPCs also upregulated the cell surface expression GLUT1 ([Figure 3D](#F3){ref-type="fig"}; also total GLUT1 by western blot, [Figure S1C](#SD1){ref-type="supplementary-material"}) and induced significantly more glucose uptake in BMPC compared with SPPC ([Figure 3E](#F3){ref-type="fig"}). Similarly, CD28 activation increased GLUT1 expression in the human MM cell lines MM.1S, U266, and KMS11 ([Figure S1D](#SD1){ref-type="supplementary-material"}). Altogether these data demonstrate that CD28 activation upregulates glucose uptake in BMPCs.

CD28 Regulates LLPC Mitochondrial Mass {#S5}
--------------------------------------

CD28 co-stimulation in T cells also regulates FAO ([@R31]). Recent studies have shown that LLPCs primarily use FAO to generate ATP ([@R35]). To determine if CD28 regulated LLPC metabolism, we first analyzed gene expression in three human CD28^+^ MM cell lines following CD28 knockdown (KD) ([@R19]), as CD28 activation in MM very closely mirrors what is seen in primary PCs ([@R8]). Several Gene Ontology pathways directly associated with mitochondrial metabolism were significantly downregulated by CD28 KD, including mitochondrial electron transport and the tricarboxylic acid cycle ([Figure 4A](#F4){ref-type="fig"}). This led us to examine whether CD28 activation affected mitochondria in primary PCs. We found that freshly isolated WT BMPCs had significantly greater mitochondrial mass compared with SPPCs using the mitochondrial dye MitoTracker Green ([Figure 4B](#F4){ref-type="fig"}). This difference was confirmed by using a different mitochondrial dye (MitoTracker Deep Red; [Figure S2A](#SD1){ref-type="supplementary-material"}) and separately by staining for the mitochondrial membrane protein voltage-dependent anion channel 1 (VDAC-1; [Figure S2D](#SD1){ref-type="supplementary-material"}), which is widely used as a measure mitochondrial mass ([@R63]). Furthermore, these direct findings were supported by increased mRNA expression of genes for six mitochondrial membrane-resident proteins (*vdac1 and 2, tomm20, tomm70a, ugcr10,* and *sucla2*) in BMPCs versus SPPCs ([Figure S2E](#SD1){ref-type="supplementary-material"}, from the dataset used in [Figure 1B](#F1){ref-type="fig"}). Direct involvement of CD28 in regulating LLPC mitochondrial mass was suggested by the significantly lower mitochondrial mass of CD28-AYAA BMPCs versus WT BMPCs ([Figure 4C](#F4){ref-type="fig"}; [Figure S2D](#SD1){ref-type="supplementary-material"} by VDAC-1). Internal control staining of BM B220^+^ B cells in these same samples was not different between WT and CD28-AYAA mice ([Figure S2B](#SD1){ref-type="supplementary-material"}).

To directly assess CD28's effect, WT BMPCs were activated by anti-CD28 mAb *in vitro* and mitochondrial mass quantified. Although cell viability was equivalent in all conditions, CD28 activation significantly increased mitochondrial mass in BMPCs ([Figure 4D](#F4){ref-type="fig"}; [Figure S2C](#SD1){ref-type="supplementary-material"} for MitoTracker Deep Red staining), while this did not occur in SPPCs (data not shown). This finding that CD28 activation upregulated mitochondrial mass in LLPC predicts an increased capacity to use mitochondrial respiration.

CD28 Enhances LLPC Mitochondrial Respiration {#S6}
--------------------------------------------

Given the metabolic heterogeneity of the BMPC population ([@R36]), we used PC cell line models that we have found to recapitulate primary LLPC biology to more precisely interrogate a role for CD28 in LLPC metabolism ([@R61]). The murine PC line XXO responds to CD28 activation but has heterogeneous CD28 expression, so we began by flow-sorting into CD28^high^ and CD28^low^ populations ([Figure 5A](#F5){ref-type="fig"}). Both expressed comparable levels of CD80 and CD86 ([Figure S3A](#SD1){ref-type="supplementary-material"}), which allows endogenous CD28 activation ([@R19]; [@R51]) and comparison of CD28^high^ versus CD28^low^ XXO metabolic profiles without exogenous CD28 activation. We first examined glycolysis by real-time measurement of the extracellular acidification rate (ECAR), an approach that has been established for T cells and LLPCs ([@R35]; [@R75]). Both CD28^high^ and CD28^low^ XXO cells had equivalent baseline acidification prior to glucose addition (the baseline metabolic activity is typical for transformed cells), and there was no difference in the glycolysis rate upon glucose addition ([Figure 5B](#F5){ref-type="fig"}). In contrast, the oxygen consumption rate (OCR) as a readout of mitochondrial respiration was significantly higher in CD28^high^ (both basal and maximal OCR) versus CD28^low^ XXO cells ([Figure 5C](#F5){ref-type="fig"}). This was also seen under stress conditions caused by serum starvation, in which although the OCR values were an order of magnitude lower than in full-serum conditions, CD28^high^ XXO cells maintained higher basal and maximal respiration ([Figure 5D](#F5){ref-type="fig"}). To corroborate these findings using direct exogenous CD28 activation, we repeated these studies in the CD28-responsive murine PC cell line J558 ([@R62]) with high CD28 expression ([Figure 5E](#F5){ref-type="fig"}) but very low or absent expression of CD80 and CD86 ([Figure S3B](#SD1){ref-type="supplementary-material"}). Direct CD28 activation with anti-CD28 mAb significantly increased the maximal respiratory capacity of J558 cells in both full-serum ([Figure 5F](#F5){ref-type="fig"}, left) and serum-free ([Figure 5F](#F5){ref-type="fig"}, right) conditions, while the effect on basal OCR was more variable. We similarly find that CD28 activation increases basal and maximal mitochondrial respiration in the human MM cell line MM.1S ([Figure 5G](#F5){ref-type="fig"}). These finding demonstrate that CD28 activation significantly enhances the oxidative respiratory capacity of LLPCs.

CD28 Induces ROS-Mediated Pro-survival Signaling {#S7}
------------------------------------------------

Increased mitochondrial mass/respiration should result in increased basal levels of reactive oxygen species (ROS), a major byproduct of oxidative phosphorylation. Consistent with the differences in mitochondrial mass, freshly isolated WT BMPCs had higher levels of total ROS versus SPPCs ([Figure 6A](#F6){ref-type="fig"}), while B220^+^ B cells from the same samples had lower levels of ROS and no differences between BM and SP ([Figure S4A](#SD1){ref-type="supplementary-material"}). This was also seen using the mitochondrial ROS-specific dye MitoSOX ([Figure S4B](#SD1){ref-type="supplementary-material"}). Similarly, the percentage of ROS^high^ BMPCs from CD28-AYAA mice was significantly lower compared with WT BMPCs ([Figure 6B](#F6){ref-type="fig"}), paralleling the differences in mitochondrial mass. Direct activation of CD28 increased ROS production in WT BMPCs ([Figure 6C](#F6){ref-type="fig"}) while having no effect on SPPCs ([Figure S4C](#SD1){ref-type="supplementary-material"}). This was also consistent with observation that genes associated with cellular responses to hydrogen peroxide were most significantly downregulated by CD28 KD ([Figure 4A](#F4){ref-type="fig"}).

Given the seeming paradox that CD28 enhances survival but ROS damage cells, we evaluated if ROS had any effect on CD28-mediated LLPC survival using the superoxide dismutase (a ROS scavenger) mimetic Euk 134. Unexpectedly, ROS scavenging completely abrogated the ability of CD28 activation to rescue WT BMPC survival from serum starvation ([Figure 6D](#F6){ref-type="fig"}), which was also seen with the pan-ROS scavenger N-acetylcysteine ([Figure S4D](#SD1){ref-type="supplementary-material"}). ROS scavenging had no effect on SPPC survival (data not shown), indicating that the loss of ROS was not non-specifically inhibiting all PC pro-survival signals.

CD28 activation-induced ROS production activates NF-κB signaling in T cells ([@R40]), and CD28 activation induces NF-κB signaling in both LLPCs and MM ([@R2]; [@R61]). We therefore evaluated whether CD28-induced ROS was involved in downstream NF-κB activation by assessing nuclear translocation of the NF-κB subunit RelA (which is activated by CD28 in LLPCs; [@R61]) in purified WT BMPCs ± anti-CD28 mAb ± Euk134. We found that ROS inhibition diminished the ability of CD28 activation to induce RelA nuclear translocation ([Figures 6E](#F6){ref-type="fig"} and [6F](#F6){ref-type="fig"}), indicating that ROS are an important component of CD28-driven NF-κB signaling.

These data suggest that ROS from other sources (e.g., generated during B cell differentiation into PBs; [@R55]) enables CD28 signaling through NF-κB in PC, and then the CD28-mediated increase in mitochondrial mass and ROS generation reinforces CD28 signaling (triggered by engagement with the LLPC niche) to maintain increased LLPC oxidative respiratory capacity. Consistent with signal reinforcement, ROS inhibition abrogated the CD28-mediated increase in maximal respiration in J558 ([Figure 6G](#F6){ref-type="fig"}) and similarly decreased the maximal oxygen consumption in CD28^high^ but not in CD28^low^ XXO cells ([Figure 6H](#F6){ref-type="fig"}), while not affecting glycolysis (data not shown). Furthermore, ROS scavenging inhibited the CD28 activation-induced maximal respiration in human MM.1S cells ([Figure 6I](#F6){ref-type="fig"}) and blocked the ability of CD28 to rescue these cells from serum starvation-induced death ([Figure S4E](#SD1){ref-type="supplementary-material"}). Altogether, these findings suggest that the increased metabolic capacity induced by CD28 activation is reinforced by an increase in the metabolic byproduct (ROS).

CD28 Induces IRF4 Expression in BMPCs, and IRF4 Levels Are Associated with BMPC Metabolic Regulation and CD28-Mediated Survival {#S8}
-------------------------------------------------------------------------------------------------------------------------------

CD28 co-stimulation in T cells regulates a distinct set of transcriptional networks involved in glycolysis and mitochondrial respiration ([@R15]; [@R58]). Interferon regulatory factor 4 (IRF4) is a transcription factor that regulates many of the same metabolic processes, including glucose uptake, mitochondrial mass, and oxidative phosphorylation in T cells ([@R41]; [@R42]), although a direct connection in T cells between CD28 and IRF4 has not been reported. However, CD28 KD in MM cells results in decreased IRF4 mRNA and protein ([@R19]). IRF4 is also a target of NF-κB in B cells ([@R24]) and is required for PC survival ([@R73]). This raises the possibility that CD28 is programming LLPC metabolism through IRF4. Consistent with this, we found higher IRF4 expression in WT BMPCs versus SPPCs ([Figure 7A](#F7){ref-type="fig"}) but no difference in IRF4 expression in the B220^+^ B cells in these same samples ([Figure S5A](#SD1){ref-type="supplementary-material"}).

To determine if CD28 can directly regulate IRF4 expression, we activated CD28 on purified WT BMPCs for 4 h and found significantly increased IRF4 mRNA expression by qPCR ([Figure 7B](#F7){ref-type="fig"}). Graded IRF4 expression drives T cell and PC differentiation ([@R34]; [@R66]) and positively regulates the expression of the key PC transcription factor BLIMP1 ([@R30]). We examined the effect of IRF4 expression levels by analyzing the gene dose effect in *IRF4*^+/+^ (WT), *IRF4*^+/−^ (which have decreased IRF4 expression compared with WT; [Figure 7C](#F7){ref-type="fig"}), and *IRF4*^−/−^ mice. *IRF4*^−/−^ mice had no PCs (in SP or BM), and *IRF4*^+/−^ had fewer PCs compared with *IRF4*^+/+^ mice ([Figure 7D](#F7){ref-type="fig"}), with no difference in CD28 expression between the *IRF4*^+/−^ and *IRF4*^+/+^ BMPC (data not shown).

The dependence of PC on IRF4 for survival presents a major experimental obstacle of directly determining the role of CD28-induced IRF4 upregulation on LLPC metabolism. However, if IRF4 is involved in CD28 regulation of LLPC metabolism, decreased IRF4 expression in *IRF4*^+/−^ BMPC should mirror what is seen in CD28-AYAA BMPCs. Consistent with this, *IRF4*^+/−^ BMPC had lower glucose uptake ([Figure 7E](#F7){ref-type="fig"}), mitochondrial mass ([Figure 7F](#F7){ref-type="fig"}), and ROS levels ([Figure 7G](#F7){ref-type="fig"}) versus *IRF4*^+/+^ BMPCs. If the changes in the *IRF4*^+/−^ BMPCs reflect disruption of CD28 signaling, this predicts a diminution of the pro-survival effect of CD28 activation. To directly test this, WT or *IRF4*^+/−^ BMPCs were co-cultured with WT DCs *in vitro*, which we have previously shown protects WT LLPCs from serum starvation-induced death through a mechanism mediated almost entirely by PC CD28 engagement with DC CD80/CD86 ([@R61]). In comparison with the significant rescue of WT BMPC survival with DC co-culture, rescue of *IRF4*^+/−^ BMPC survival was significantly attenuated ([Figure 7H](#F7){ref-type="fig"}). To better control the comparison between IRF4-replete and IRF4-deficient PCs, we knocked down IRF4 in human MM MM.1S cells using two different small interfering RNA (siRNA) constructs that consistently caused different degrees of IRF4 KD ([Figure 7I](#F7){ref-type="fig"}, left), which did not affect CD28 expression (data not shown). IRF4 KD reduced MM.1S survival in both full-serum and serum-free conditions, which reflected the degree of KD and significantly abrogated the ability of direct CD28 activation to rescue MM.1S survival in serum-free conditions ([Figure 7I](#F7){ref-type="fig"}, right). This is consistent with our previous findings in MM, in which increasing CD86 expression could not protect against IRF4 silencing-induced death ([@R19]). Altogether these data indicate that CD28's effects on LLPC metabolism and survival are mediated by further upregulation of IRF4 expression.

DISCUSSION {#S9}
==========

Durable protective humoral immunity is dependent on continual Ab production by LLPCs. LLPCs can survive for years, but the basis of their longevity is unclear. We have previously reported that activation of CD28 expressed on PCs is necessary for the survival of LLPCs but not SLPCs within their niches, even though both LLPCs and SLPCs have equivalent CD28 expression ([@R61]). However, another study showed that CD28 in the B lineage constrains the number of SPPCs and BMPCs generated after vaccination, in particular IgM^+^ PCs (and to a lesser extent IgG^+^ PCs) at notably early time points (days 7 and 18 after immunization), with loss of PC CD28 amplifying Ag-specific IgM and IgG responses ([@R53]). This suggests that intrinsic CD28 signaling regulates PC biology at two distinct stages, during initial PC generation and in the maintenance of LLPCs in peripheral niches. A role for CD28 in PC generation is supported by our finding that a threshold of SLP76 and ROS expression is needed to enable CD28 signaling (discussed below), and these thresholds are likely set early in B cell to PC differentiation.

We have now found a previously unrecognized role for SLP76 in linking the CD28 receptor to downstream pro-survival signaling in high-SLP76-expressing LLPCs but not low-expressing SLPCs. Our transcriptomic analysis revealed increased *Lcp2* expression in BMPCs versus SPPCs and in a separate dataset that *Lcp2* was highly upregulated in murine B220*−*CD138^+^ PBs *in vivo*. It should be noted that other available datasets do not show a clear upregulation of *Lcp2* in LLPCs ([@R25]; [@R36]), although this may be due to heterogeneity in the PC subsets analyzed (e.g., in [@R25], only 27% of the human BMPC subset containing LLPCs expressed CD28) or the difficulty in detecting low-level transcripts by single-cell RNA sequencing (RNA-seq) among the abundance of Ig transcripts ([@R36]). However, we found higher SLP76 protein expression in BMPCs versus SPPCs. Furthermore, functional analysis of SLP76-KI PCs directly demonstrated the requirement for SLP76 capable of binding Vav to transduce CD28's pro-survival signal in BMPCs. This was reflected *in vivo*, where the selective loss of the BMPC population in the SLP76-KI mice closely mirrors the same loss in CD28-AYAA-KI mice that lack CD28/Grb2/Vav signaling. These *in vivo* studies, however, only narrowly interrogate the role of SLP76 in CD28 signaling in LLPCs and do not comprehensively examine SLP76's broader function (either intrinsic or extrinsic) in overall PC biology.

Altogether these findings suggest that the conditions that "set" SLP76 expression during PC generation in the lymph node play a pivotal role in determining the fate of that PC, by determining whether it can use CD28 activation for survival once in the LLPC niche. Interestingly, the level of SLP76 expression alone likely does not explain why CD28 signals by itself (without a signal 1) in LLPCs but not in T cells, as T cells had higher SLP76 expression compared with BMPCs.

Recent studies have identified a distinct metabolic signature of increased glucose uptake and mitochondrial respiratory capacity in regulating LLPC survival and function ([@R35], [@R36]). However, what initiates and sustains this metabolic program is unknown. Because of CD28's regulation of glucose metabolism in T cells, we predicted that CD28 activation could regulate glucose in LLPCs. Consistent with this, we found that CD28 signaling upregulated glucose uptake in LLPCs. In the SPPC population, we found more variable glucose uptake that did not resolve distinct SPPC subpopulations as reported by others ([@R35], [@R36]). However, this difference is likely technical in nature, as the NBDG uptake and staining in our *in vitro* conditions were significantly lower compared with the *in vivo* methods used by the previous studies. *In vivo* studies of CD28's role in PC glucose uptake are experimentally challenging, given that loss of CD28 preferentially depletes the LLPC population that has been separately shown to be the PC subset with the highest glucose uptake. Thus, it cannot be differentiated whether any changes in *in vivo* PC NBDG uptake in the CD28-knockout (KO)/KI versus WT mice are due to changes in CD28-mediated PC-intrinsic glucose uptake versus loss of the NBDG^hi^ LLPC subset through separate mechanisms. However, *in vitro*, we found that the defect in CD28-AYAA BMPC glucose uptake accounts for only about 20% of the total glucose uptake of the WT LLPCs and matches CD28-mediated increases in LLPC GLUT1 expression and glucose uptake *in vitro*. Thus, CD28 is likely one of multiple factors regulating LLPC glucose uptake, possibly playing a more important role under stress conditions, as we have seen in myeloma ([@R51]) and has been proposed for mitochondrial pyruvate metabolism ([@R35]). Interestingly, CD28-AYAA SPPCs also took up less glucose. This may be a consequence of the loss of ROS in the CD28-AYAA mutant, as ROS negatively regulate the phosphatase PTEN, which inhibits PI3K signaling ([@R37]), and the resulting downregulation of PI3K signaling may suppress glucose uptake.

Unlike in T cells, we found that CD28 activation does not upregulate glycolysis in LLPCs, nor does CD28 KD result in significant changes in the glycolytic pathways in MM cells. Rather, CD28 activation significantly upregulated oxidative mitochondrial respiration, which dovetails with the observation that LLPCs primarily use fatty acids for basal respiration ([@R35]). CD28 co-stimulation in T cells has been elegantly shown to increase mitochondrial FAO and regulate mitochondrial mass/morphology necessary for memory T cell generation ([@R31]). Mirroring this biology, we found that mitochondrial mass in WT LLPCs was significantly greater than SLPCs and that CD28-AYAA LLPCs had significantly less mitochondrial mass compared with WT. Other reports have found no differences in mitochondrial mass between SLPCs and LLPCs ([@R35]), though these studies were in recently immunized mice, while ours were in steady-state unvaccinated mice. The molecular basis by which CD28 activation increases mitochondrial mass in LLPCs is unclear. Although expression of the master regulator of mitochondrial biogenesis PGC1α is higher in BMPCs versus other B lineage subsets (probe 219195_at; [@R72]), we found that CD28 activation does not further increase PGC1α expression, similar to what has been reported in T cells ([@R44]). We have found that PGC1β is overexpressed in human MM (unpublished data), and we are pursuing this as a potential mediator of CD28's mitochondrial effects.

The observation that CD28 induces ROS production in LLPCs led to the unexpected finding that ROS are necessary for CD28 signaling downstream to NF-κB, positioning ROS both upstream and downstream of CD28's effect on the mitochondria. ROS have been shown to regulate the activation of the NF-κB for cell survival in other cell types ([@R65]), and CD28-mediated NF-κB activation is diminished by ROS inhibition in T cells ([@R40]). Whether ROS are necessary to facilitate initial CD28 signaling in PCs, and where those ROS come from, is not known. It has been shown, however, that B cell differentiation into PBs requires a stepwise switch from glycolysis to oxidative phosphorylation with an accompanying increase in ROS ([@R55]). One possibility is that multiple processes in B cell activation and differentiation to PBs/PCs generate ROS, with high levels of ROS enabling CD28 signaling in PCs. This in turn allows CD28 to regulate initial PC generation as well as transduce a pro-survival signal in PCs that access the LLPC niche. Once in the niche, ROS generated by the CD28-mediated increase in mitochondrial mass/metabolism reinforce niche-driven CD28 signaling to sustain LLPC metabolic fitness and survival. This model further suggests that other signals/feedbacks that regulate mitochondrial activity/ROS production can influence ROS levels and thus CD28 signaling. ROS levels may therefore be a convergent regulatory node for LLPC survival and function. It is also interesting to speculate that high ROS levels allow CD28 to signal in LLPCs without a signal 1, by lowering the threshold for downstream NF-κB activation.

The ability of CD28 to regulate glucose uptake and mitochondrial metabolism in LLPCs led us to hypothesize that IRF4, known to regulate these metabolic pathways in T cells ([@R41]), would be a downstream target of CD28 activation in LLPCs. We found that direct CD28 activation increased IRF4 expression on LLPCs. Similarly, CD28 KD in MM cell lines results in decreased IRF4 mRNA expression ([@R19]). However, IRF4 is a challenging transcriptional factor to interrogate in PC biology, as conditional deletion leads to rapid cell death ([@R73]). We therefore made use of the graded IRF4 protein expression in *IRF4*^+/+^ and *IRF4*^+/−^ PCs and found that higher IRF4 expression correlated with CD28-responsive metabolic pathways in LLPCs, including glucose uptake, mitochondrial mass, and ROS. Consistent with this, the pro-survival effect of CD28 activation was significantly attenuated in *IRF4*^+/−^ BM PCs as well as MM cell lines knocked down for IRF4. Direct measurement of metabolism are ongoing but are challenging given the small number of cells (*IRF4*^+/−^ PC) and the rapid induction of death by IRF4 KD (in the MM cells). The finding that the *IRF4*^+/−^ mice also have diminished SPPC populations clearly suggests that IRF4 is involved in other pathways that regulate PC metabolism and/or survival.

Altogether, our findings identify a previously unrecognized molecular network regulating LLPC survival, whereby CD28 activation on LLPCs signals through SLP76 to provide an essential pro-survival signal, and differences in SLP76 expression between LLPCs and SLPCs account for the inability of the latter to use this survival pathway. CD28 activation leads to increased LLPC glucose uptake, mitochondrial mass, and respiratory capacity to augment the metabolic fitness of LLPCs for survival. ROS production resulting from higher mitochondrial respiration then reinforces pro-survival/enhanced metabolism signaling downstream of CD28 activation in LLPCs. CD28-induced signaling then increases IRF4 expression to augment the metabolic program, which we propose crucially enhances the metabolic fitness of LLPCs in the hypoxic/nutrient-poor BM microenvironment.

STAR★METHODS {#S10}
============

RESOURCE AVAILABILITY {#S11}
---------------------

### Lead Contact {#S12}

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Kelvin Lee (<kelvin.lee@roswellpark.org>).

### Materials Availability {#S13}

This study did not generate new unique reagents.

### Data and Code Availability {#S14}

This study did not generate any unique datasets or code.

EXPERIMENTAL MODEL AND SUBJECT DETAILS {#S15}
--------------------------------------

### Cell culture {#S16}

The MM cell line MM.1S (human, female, RRID: CVCL_8792), XXO (murine, BALB/c, RRID: CVCL_4696), and J558 cells (murine, BALB/c, RRID: CVCL_3529) (all ATCC) were maintained in RPMI 1640 (CellGro, Corning NY), 10% fetal bovine serum (Thermo Fisher Scientific Hyclone, Waltham, MA), 100U/mL Penicillin, 100ug/mL streptomycin, and 2nM L-glutamine (all CellGro) at 37°C in 5% CO~2~. Cells were passaged every 2-3 days for a maximum of 30 days, with cells split to 2x10^5^ cells/mL each passage.

### Mice {#S17}

Procedures were approved by the Institutional Animal Care and Use Committee at Roswell Park Comprehensive Cancer Center. Retired female C57Bl6/N (6-8 month old, Charles River) and age/sex matched CD28-AYAA knock-in (CD28-AYAA), IRF4^+/−^, and *IRF4*^−/−^ mice were housed in pathogen-free facilities. Age matched 6-8 week old female littermates (WT C57Bl6/N and SLP76 Y112-128F knock-in mice) were housed at the University of Pennsylvania.

METHOD DETAILS {#S18}
--------------

### Tissue Processing and Plasma Cell Isolation {#S19}

Bone marrow from femurs/tibias was flushed with cold PBS into 50mL conical tubes on ice. Spleens were similarly harvested into cold PBS. BM and spleens were homogenized by filtration through a 40 μM mesh screen and pelleted by spinning at 1000rpm for 5 minutes at 4°C. PBS was decanted, and 1mL ACK lysis buffer/1x10^8^ cells (Thermo Fisher) was added and pipetted gently 3-4x. ACK buffer was diluted to 25mL with cold MACS buffer (PBS, 2% FBS, and 1mM EDTA). Cells were filtered with a 40 μM mesh screen and spun at 1000rpm for 5 minutes at 4°C. Plasma cell isolation was done as per manufacturer's instructions (Mouse CD138+ Isolation Kit, Miltenyi).

### ImageStream {#S20}

Plasma cells were fixed in 4% formaldehyde for 30 minutes at 4°C, washed in PBS and permeabilized with 0.1% Triton X with 10% serum for blocking. A 1:100 dilution of RelA (p65) antibody from Cell Signaling (6956S) was added for 1 hr at 4°C for 1 hr, and washed in permeabilization buffer. 1:100 mouse anti-goat IgG-FITC (Santa Cruz sc-2356) was added for 15 minutes at room temp. Cells were washed in PBS, and resuspended in 30 μL PBS for ImageStream processing. DAPI (10 μM) was added to cells as a nuclear stain immediately prior to running through ImageStream machine. Analysis gated on single cells, in focus, double positive for nuclear stain and RelA/p65.

### Analysis of RNA-seq data {#S21}

Data from Gavile et al. was analyzed as previously described ([@R19]). Briefly, genes differentially expressed between vector control and shCD28-infected cell lines were previously determined using edgeR (v3.12.1). Gene ontologies enriched in down- and upregulated genes were determined by GOstats (v2.36.0). Expression of mRNA used FPKM (fragments per kilobase per million reads) normalized read counts and heatmap representations were made using custom R (v3.6.0) code available upon request.

### ELISPOT {#S22}

Total IgG ASC was quantified by ELISpot assay as per manufacturer's instructions (Mabtech). In brief, 96-well plates (Millipore) were precoated with 15 μg/ml anti-IgG capture antibody in PBS for 16hrs. 1x10^5^ bone marrow mononuclear cells from either WT or SLP76 KI mice were then plated for 24hrs before assessing number of IgG secreting cells.

### RNA Isolation and qPCR {#S23}

The purification of total RNAs was prepared using the RNeasy mini kit (QIAGEN \#74104) as per Purification of Total RNA, Including Small RNAs, from Animal Cells Protocol. Up to 1 × 10^7^ of cultured cells are first centrifuged to obtain a cell pellet, then disrupted by resuspending the pellet in 700 ul of QIAzol Lysis Reagent and pipetting up and down. After addition of chloroform, the homogenate is then separated into aqueous and organic phases by centrifugation. RNA partitions to the upper, aqueous phase, while DNA partitions to the interphase and proteins to the lower, organic phase or the interphase. The upper, aqueous phase is extracted, and ethanol is added to provide appropriate binding conditions for all RNA molecules from 18 nucleotides upward. The sample is then applied to the RNeasy Mini spin column, where the total RNA binds to the membrane and phenol and other contaminants are efficiently washed away. On-column DNase digestion is also performed to remove any residual genomic DNA contamination followed by additional washes. High quality RNA is then eluted in 20 - 25 ul of RNase-free water. Quantitative assessment of the purified total RNA is then accomplished by using a Qubit high Sense RNA kit (Thermofisher \#Q32854). The RNA is further evaluated qualitatively by a Tapestation Analysis (Agilent technologies).

Reverse Transcriptase (RT) reactions for each sample were processed with the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems \#4368814). 8.7 to 200ng of RNA (sample dependent) was mixed with 0.8uL 25x dNTP Mix, 2uL 10x Random Primers, 2uL 10x RT Buffer, 1uL Multiscribe Reverse Transcriptase, plus 4.2uL H~2~O for each sample in 0.2mL Thin-walled PCR tubes (Applied Biosystems \#AB-1113) and the RT reactions were run on a Bio-Rad C1000 Touch Thermal Cycler with a four step program (Step 1 - 25°C 10 min, Step 2 - 37°C 120 min, Step 3 - 85°C 5 min, and Step 4 - 4°C hold).

Quantitative PCR (qPCR) was performed on a MicroAmp - Optical 384-well Reaction Plate (Applied Biosystems \#4309849) with the Power SYBR Green Master Mix (Applied Biosystems \#4368577). Reverse Transcription (RT) reactions were diluted then 2uL/well was loaded on the plate; samples were done in triplicate. A mix of Power SYBR Green Master Mix, forward and reverse primer mix, and water was combined for each target gene and 8uL aliquoted into wells for each set of samples, such that each well had 5uL of Power SYBR green master mix, 2.5uL of primer mix at 1uM, and 0.5uL H~2~O for a total volume with cDNA of 10uL/well. The qPCR was run on the Applied Biosystems QuantStudio 6 Flex Real-Time PCR System and analyzed with Applied Biosystems QuantStudio Real-Time PCR Software v1.2.

### Extracellular Flux Assays {#S24}

For all extracellular flux assays, cells were plated on Cell-Tak coated Seahorse XF96 cell culture microplates at a density of 8x10^4^ cells per well. The assay plates were spin seeded for 5 minutes at 1,000 rpm and incubated at 37°C without CO~2~ prior to performing the assay on the Seahorse Bioscience XFe96. The Mitochondrial Stress Test was performed in XF Base Media containing 10 mM glucose, 1 mM sodium pyruvate, and 2 mM L-glutamine and the following inhibitors were added at the final concentrations: Oligomycin (2 μM), carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone (FCCP) (2 μM), Rotenone/Antimycin A (0.5 μM each). The Glycolytic Stress Test was performed in XF Base Media containing 2 mM L-glutamine and the following reagents were added at the final concentrations: Glucose (10 mM), Oligomycin (2 μM), and 2-deoxy-glycose (50 mM).

### Flow Cytometry {#S25}

MitoTracker Green FM (200 nM), MitoTracker Deep Red (100 nM), MitoSOX Red (5 μM), CM-DCFDA (10 μM Invitrogen, Molecular Probes), and 2NBDG (100 μg/mL), anti-B220-BV421 (clone RA3-6B2) and anti-CD138-APC (clone 281-2) from Biolegend, anti-VDAC1/Porin antibody (Abcam clone 20B12AF2, 0.2 μg/mL), Live Dead Blue Dye (Thermo Fisher), GLUT1 (Abcam ab15309). For MitoTracker Green/DR, MitoSox staining, BM and SP cells were plated in serum free media at 2x10^6^/well and incubated at 37°C for 20 minutes with dyes. Cells were then stained washed and stained in PBS for CD138 and B220. Samples were analyzed using a Fortessa B for FACs analysis. Flow analysis was done using FlowJo.

Intracellular staining: BM and SP mononuclear cells were isolated and stained with for CD138-PE, B220-BV421, and CD3-APC. Following surface staining, the cells were resuspended in FoxP3 fixation/permeabilization solution (eBioscience), washed and stained with 1:100 dilution of primary sheep anti-mouse anti-SLP76 mAb (Santa Cruz, clone H300) followed by 1:100 dilution of goat anti-rabbit IgG-FITC (Santa Cruz sc-2012) in 1X buffer with 5% FBS. Samples were analyzed using an LSRII for FACS analysis, gating on CD3^+^ cells for T cells and B220^low^/CD138^+^ for plasma cells.

For ROS staining, BM and SP were plated in serum free media at 2x10^6^/well and incubated at 37°C for 15 minutes prior to activation. Cells were treated with 25 μg/well of control hamster Ig or anti-CD28 mAb (PV1) for 2 hr, washed and stained for B220, CD138 and 10 μM CM-DCFDA. For analysis, CD138^+^/B220^−^ cells were gated and the MFI was assessed on the FITC channel.

All cell sorting was done with the FACS Aria II by staining with CD28 (PE conjugate) and separating cells based on positive and negative expression levels. Cells were then cultured as described for 3 days prior to experimental use. Flow analysis was done using FlowJo.

### BM-derived dendritic cell (BMDC) generation and co-culture viability assay {#S26}

BM from C57BL/6 WT were used to generate BMDC. BM cells were taken from the tibia and femurs of age matched mice and put into culture in 6 well plates with 20ng/mL recombinant murine GM-CSF (Miltenyi mouse recombinant GM-CSF research grade 130-094-043) for 7 days at a concentration of 1e6 cells/mL, 2mL per well. On day 3 and 5, 1mL was taken from each well and replenished with fresh media with 20ng/mL of GM-CSF. Co-culture experiments: PC were purified from the bone marrow of C57BL/6 or *IRF4*^+/−^ mice. Co-culture was plated in a 96 well plate at a 1:2 ratio, 20,000 PC with or without 40,000 BMDC in 0.2mL of culture medium/well (10% FBS RPMI) supplemented with 10ng/mL GM-CSF at 37°C with 5% CO~2~. DC were stained with Cell Trace Violet dye (ThermoFisher) to differentiate from PC. To assess viability, cells were taken directly from culture wells and stained with Live Dead Blue Fixable Viability Dye (Thermo Fisher) and CD138-APC (Biolegend). Viability was assessed both as percentage live and total live cells (based off cell number plated).

### CD28 activation {#S27}

Activation of human and murine CD28 was performed using 10 μg/mL anti-human CD28 mAb (Beckman Coulter, clone 28.2). For murine CD28, anti-murine CD28 mAb (BioXCell clone PV1), polyclonal control hamster-IgG {Genetex) were coated on polystyrene plates at 20 μg/mL for 12 hr at 4°C prior to cell addition.

### Western blots {#S28}

Cells were treated as indicated. Cell pellets were collected and frozen. Cells were lysed with Lysis Buffer (50 mM Tris HCl, 150 mM NaCl, 1% NP40, 1mM PMSF, 0.4 mg/ml NaF, 0.4 mg/ml NaVO4, 1 Pierce protease inhibitor tablet (Thermofisher, A32965)) and protein concentration was determined by BCA assay (Thermofisher, 23227). Equal amounts of protein were separated by SDS-PAGE and transferred to PVDF membranes (Millipore, IPVH00010) through wet transfer in Towbin buffer. Membranes were blocked in BSA and TBST for 30 minutes and incubated in primary antibodies for 16h. Membranes were then incubated in HRP-linked secondary antibodies for 1h and developed using Pierce ECL (Thermofisher, 32209) and the Li-Cor Odyssey Fc digital imaging system (Li-Cor). Protein concentration was estimated using the Image Studio software (Li-Cor).

### IRF4 knockdown {#S29}

MM1.S were transfected using the Amaxa Nucleofector II system from Lonza (Kit V, VVCA-1003). Cells were transfected with 1 μM ON-TARGETplus constructs: siControl 1 (Horizon Discovery D-001810-01-05, UGGUUUACAUGUCGACUAA), siIRF4 \#1 (Horizon Discovery J-019668-07-0002, CAUCACAGCUCACGUAGAA) and siIRF4 \#2 (Horizon Discovery J-019668-08-0002, CCACAGAU CUAUCCGCCAU). Transfected cells were incubated for 4 hours in complete media then used in viability assays as described. Cells were verified for knockdown efficiency after 48 hours by IRF4 western blot as described. Equal numbers of MM1.S cells for each transfection were incubated for 48 hours in complete media as described supplemented with 10% FBS or serum free media with 10 μg/ml of either anti-CD28 (Beckman Coulter B62001, clone 28.2) or Mouse IgG1 (BioXCell BE0083, clone MOPC-21). Cells were harvested and viability was determined by Trypan Blue exclusion. Survival percentage was determined by setting the full serum siControl to 100% and reflects an average of three trials.

### T cell isolation/activation {#S30}

Peripheral T cells were isolated from the spleens of 6-12 week old WT and CD28-AYAA female mice via negative selection using the EasySep Mouse T cell Isolation Kit (Stem Cell Technologies) and cultured in complete RPMI medium (10% FBS, 1% L-Glutamine, 1% Penicillin/Streptomycin, 0.5% HEPES). Cultured T cells were activated by αCD3, αCD28 antibodies (MiltenyiT Cell Activation/Expansion Kit) and 1ng/ml rIL-2.

QUANTIFICATION AND STATISTICAL ANALYSIS {#S31}
---------------------------------------

All statistical analysis was done using GraphPad Prism 7. In [Figure 1A](#F1){ref-type="fig"}, ordinary 2-way ANOVA was used for all cell types and genotypes. Student's t test was performed for statistical analysis using two-tailed, non-equal variances, and 95% Confidence Interval. For statistical analysis of PC/T cell Seahorse data, final readings of basal oxygen consumption, maximal oxygen consumption, or glycolysis were compared between each of the technical replicates between treatments by Student's t test. Error bars are ± SD. Notation in the figure legends: NS-not significant, \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001, \*\*\*\*p \< 0.0001
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![SLP76 Is Differentially Expressed in BMPCs versus SPPCs\
(A) *Lcp2* mRNA expression in B cell and PC subsets (probe 205269_at) in the Amazonia database.\
(B) *Lcp2* expression in B220^+^ B cells from naive mice, SP B220^+^CD138^+^ plasmablasts, and B220^−^CD138^+^ PCs from LPS-treated mice (D3) by Illumina microarray. \*\*p \< 0.01, \*\*\*p \< 0.001.\
(C) Analysis from purified BMPC and SPPC samples using Affymetrix probe 1418641_at, normalized and annotated with the Affy and Limma Bioconductor packages in R. Statistical analysis was done between non-transformed expression values of BMPCs and SPPCs using Student's t test. \*p \< .05.\
(D) Total WT SP and BM mononuclear cells (MNCs) stained for CD138, B220, and CD3, then for intracellular SLP76, and analyzed using flow cytometry of the indicated populations versus FMO (full minus one control). Quantification of SLP76 expression in BMPCs and SPPCs as normalized mean fluorescence intensities (MFIs) (MFI of SLP76 minus FMO) pooled from two independent experiments is shown on the right. \*p \< .05.\
Statistical analysis by two-way ANOVA; annotation key in [STAR Methods](#S10){ref-type="sec"}. Error bars represent ± SD.](nihms-1607449-f0002){#F1}

![SLP76 Is Required for CD28-Mediated LLPC Survival\
(A and B) Purified PCs from BM (A) or SP (B) of WT or SLP76-KI mice were treated with control Ig or anti-CD28 mAb-coated beads for 16 h in serum-free media, and viability was assessed using trypan blue exclusion. Representative of two independent experiments. \*p \< .05.\
(C) Total numbers of CD3^+^ T cells and PCs from three individual WT or age-matched SLP76-KI mice were quantified using FACS. Representative of two independent experiments. \*p \< .05.\
(D) BM and SP MNCs from three WT or age-matched SLP76-KI mice were stained for CD138, B220, and CD3. Percentage BMPCs or SPPCs on the basis of gating B220^−^CD138^+^ population. Data represent two independent experiments, with the percentage PCs for six individual mice quantified. \*\*\*p \< 0.001.\
(E) BM MNCs were harvested from four WT or SLP76-KI mice and total IgG-secreting cells quantified using ELISpot. Data are representative of two independent experiments. \*\*\*p \< 0.001.\
Statistical analysis by Student's t test. Error bars represent ± SD.](nihms-1607449-f0003){#F2}

![CD28 Regulates Glucose Uptake in LLPCs\
(A) BM and SP MNCs from two WT mice were stained for CD138 and B220 and cultured in NBDG to assess glucose uptake using flow cytometry. Data are representative of three individual experiments. \*\*p \< 0.01.\
(B) SP T cells were purified from WT or age-matched CD28-AYAA mice, activated with bead-bound anti-CD3 + anti-CD28 mAb + IL-2 ×24 h, and analyzed using Seahorse XF Glycostress test. Data are representative of three independent experiments. \*\*p \< 0.01.\
(C) Level of NBDG uptake between WT and CD28KI-AYAA PCs evaluated as in (A). \*p \< .05.\
(D) Purified BMPCs and SPPCs were treated with isotype control or anti-CD28 mAb × 16 h and evaluated for GLUT1 expression using flow cytometry. Results reflective of two independent experiments with values normalized to isotype control-treated MFI. Statistical analysis performed by analyzing raw MFI between control and anti-CD28 mAb-treated cells of SPPCs and BMPCs separately. \*\*p \< 0.01.\
(E) Glucose uptake assessed by isolation and activation of SPPCs and BMPCs as in (C), evaluating NBDG uptake using flow cytometry. Analysis performed on pooled data from two independent experiments, normalizing to control-treated MFI between SPPCs and BMPCs. \*p \< .05.\
Statistical analysis by Student's t test. Error bars represent ± SD.](nihms-1607449-f0004){#F3}

![CD28 Regulates BMPC Mitochondrial Mass\
(A) RNA-seq data from MM.1S, RPMI8226, and KMS18MM cells transduced with empty vector versus shCD28. Metabolic Gene Ontologies significantly enriched in genes downregulated by shCD28 are shown on the left. The gene expression heatmap represents read count and *Z* score-normalized mRNA expression.\
(B) BM and SP MNCs from WT mice were stained for CD138, B220, and MitoTracker Green and analyzed using flow cytometry. Quantification represents raw MFI values for BMPCs and SPPCs from individual mice pooled from three independent experiments. \*\*\*\*p \< 0.0001.\
(C) BM MNCs from two WT and CD28-AYAA mice were evaluated for mitochondrial mass as in (A). Data are representative of three independent experiments. \*p\<.05.\
(D) PCs purified from BM of four WT mice were treated with isotype control or anti-CD28 mAb × 16 h, stained with MitoTracker Green, and analyzed using flow cytometry. Data are representative of three independent experiments. \*\*p \< 0.01.\
Statistical analysis by Student's t test. Error bars represent ± SD.](nihms-1607449-f0005){#F4}

![CD28 Regulates PC Mitochondrial Respiration\
(A) CD28 expression of sorted XXO cells populations using flow cytometry and western blot (1 × 10^6^ cells).\
(B) CD28^high^ and CD28^low^ XXO cells plated × 16 h in full serum evaluated for glycolysis using the Seahorse XF Glycostress test.\
(C) CD28^high^ and CD28^low^ XXO cells were plated in full serum as in (B), and mitochondrial respiration was assessed using the Seahorse XF Mitostress test. Data are representative of three independent experiments. \*\*p \< 0.01, \*\*\*\*p \< 0.0001.\
(D) CD28^high^ and CD28^low^ XXO cells plated in serum-free media × 16 h assessed for mitochondrial respiration as above. Data are representative of three independent experiments. \*\*p \< 0.01.\
(E) CD28 expression of J558 using flow cytometry. \*p \< .05.\
(F) J558 cells were treated with isotype control or anti-CD28 mAb × 16 h in full serum (left) or no serum (right), and mitochondrial respiration was determined as above. Data are representative of three independent experiments. \*\*p \< 0.01, \*\*\*\*p \< 0.0001.\
(G) MM.1S cells were treated with isotype control or anti-CD28 mAb × 16 h in full serum. Mitochondrial respiration was evaluated as above. Data are representative of three independent experiments. \*\*p \< 0.01.\
Statistical analysis by Student's t test. Error bars represent ± SD.](nihms-1607449-f0006){#F5}

![CD28 Induces ROS for BMPC Survival\
(A) WT BM and SP MNCs were stained for CD138, B220, and cellular ROS with CM-DCFDA and analyzed using flow cytometry. Quantification represents raw MFI values for BM and SP PCs from individual mice pooled from three independent experiments. \*\*p \< 0.01.\
(B) BM MNCs from two WT and CD28-AYAA mice were evaluated for ROS levels as in (A). \*p \< .05.\
(C) BM and SP MNCs were treated with isotype control or anti-CD28 × 2 h in serum-free media and then stained for B220 CD138 and CM-DCFDA. Data are representative of three independent experiments. \*p \< .05.\
(D) Purified BMPCs and SPPCs were treated with isotype control or anti-CD28 mAb × 16 h in serum-free media ± Euk 134. Survival was determined using trypan blue exclusion. Data are representative of three independent experiments. \*p \< .05.\
(E) Purified BMPCs and SPPCs were treated with isotype control or anti-CD28 mAb ± Euk 134 × 30 m, stained for NF-κB RelA/p65 and DAPI, and analyzed using ImageStream for nuclear localization. Scale bar represents 10 μM.\
(F) Change in ImageStream similarity score for NF-κB RelA/p65 nuclear localization with CD28 activation versus control (statistics above first bar) or CD28 activation ± Euk 134. Data pooled from three independent experiments. \*p \< .05.\
(G) J558 cells were treated with isotype control or anti-CD28 mAb × 16 h in full serum ± Euk 134, and oxygen consumption rate (OCR) was determined using the Seahorse XF. Quantification is representative of maximal respiration. Data are representative of three independent experiments. \*p \< .05.\
(H) CD28^high^ and CD28^low^XXO cells were plated × 16 h in full serum ± Euk 134, and OCR was measured as above. Data are representative of three independent experiments. Quantification is representative of maximal respiration. \*\*p \< 0.01.\
(I) MM.1S cells were treated with isotype control or anti-CD28 mAb × 16h ± Euk 134, and OCR was evaluated as above. Quantification is representative of maximal respiration. Data are representative of two independent experiments. \*p \< .05.\
Statistical analysis by Student's t test, except for survival experiments, which were analyzed using ANOVA with Bonferroni analysis. Error bars represent ± SD.](nihms-1607449-f0007){#F6}

![CD28 Induces Irf4 Expression in BMPCs, and Irf4 Levels Are Associated with BMPC Metabolic Regulation\
(A) WT SP and BM MNC were stained for B220, CD138, and intracellular IRF4. Comparison of IRF4 expression between SP *IRF4*^−/−^ B220^+^ cells and WT B220^−^CD138^+^ BMPCs and SPPCs. Representative of three independent experiments. \*\*\*p \< 0.001.\
(B) Purified BMPCs were treated with isotype control versus anti-CD28 mAb × 4 h in serum-free media. *Irf4* mRNA expression was determined using qPCR with actin as a loading control; fold change in expression normalized to control-treated cells. Quantitation from pooled results from two independent experiments. \*p \< .05.\
(C) Comparison of IRF4 protein expression between WT, *IRF4*^+/−^ and *IRF4*^−/−^ BMPCs. Data are representative of three independent experiments. \*\*p \< 0.01.\
(D) BM (top panel) and SP (bottom panel) MNCs from age-matched WT, *IRF4*^+/−^, and *IRF4*^−/−^ mice stained for B220 and CD138. Representative of three independent experiments.\
(E) WT and *IRF4*^+/−^ BM and SP MNCs were stained for B220, CD138, and NBDG. Representative of two independent experiments. \*p \< .05.\
(F) Mitochondrial mass between WT and *IRF4*^+/−^ BMPCs was evaluated by staining MitoTracker Green. Data are representative of three independent experiments. \*p \< .05.\
(G) ROS levels between WT and *IRF4*^+/−^ BMPCs determined by staining with CM-DCFDA. Data are representative of two independent experiments. \*\*p \< 0.01.\
(H) BMPCs (2.5 × 10^3^) of the indicated genotype were cocultured with WT BMDCs in a 1:2 ratio in serum-free media and assessed for viability using Live Dead Blue dye after 24 h. (Left) Total live PC quantification, (middle) percentage, and (right) total number of viable WT or IRF4 *IRF4*^+/−^ BMPCs. \*\*\*p \< 0.001, \*\*p \< 0.01, \*p \< .05.\
(I) MM.1S cells transfected with either siRNA control 1 (siControl) or two different siRNA constructs (siIRF4-1, siIRF4-2). Left: IRF4 knockdown in three separate experiments; densitometry is relative to siControl for each experiment. Right: transfected cells were treated with control IgG or anti-CD28 mAb in full serum (FS) or no serum for 48 h, and survival was compared with FS siControl. \*p \< .05.\
Statistical analysis by Student's t test. Error bars represent ± SD.](nihms-1607449-f0008){#F7}

###### 

KEY RESOURCES TABLE

  REAGENT or RESOURCE                               SOURCE                                        IDENTIFIER
  ------------------------------------------------- --------------------------------------------- -------------------------------------------------------
  Antibodies                                                                                      
  human anti-CD28                                   Beckman Coulter                               Cat\#IM1376; Clone 28.2
  murine anti-CD28                                  BioXCell                                      Cat\#BE0015-5; Clone PV1
  polyclonal control hamster-IgG                    Genetex                                       Cat\#GTX00619
  B220 (BV421 conjugate)                            Biolegend                                     Cat\#103239; RRID: AB_10933424; Clone RA3-6B2
  CD138 (APC conjugate)                             Biolegend                                     Cat\#142505; RRID: AB_10960141; Clone 281-2
  VDAC1/Porin                                       Abcam                                         Cat\#Ab14734; Clone 20B12AF2
  GLUT1                                             Abcam                                         Cat\#ab15309
  CD3 (APC conjugate)                               Biolegend                                     Cat\#100235; RRID: AB_2561455; Clone 17A2
  SLP76                                             Santa Cruz                                    Cat\#sc-6902; Clone H300
  anti-rabbit IgG-FITC                              Santa Cruz                                    Cat\#sc-2012
  IRF4                                              Cell Signaling                                Cat\#4948S; Clone P173
  Actin                                             Sigma                                         Cat\#A5441
  IRF4 (PE conjugate)                               Biolegend                                     Cat\#646403; Clone IRF4-3E4
  CD138 (PE conjugate)                              Biolegend                                     Cat\#142503; Clone 281-2; RRID: AB_10915989;
  murine IgG1                                       BioXCell                                      Cat\#BE0083; Clone MOPC-21
  CD86 (PE conjugate)                               Biolegend                                     Cat\#105007; Clone GL-1; RRID\# ; AB_313150
  CD80 (PE conjugate)                               Biolegend                                     Cat\#104707; Clone 16-10A1; RRID\# AB_313128
  RelA (p65)                                        Cell Signaling                                Cat\#6956S; Clone L8F8; RRID\# AB_10828935
  Chemicals, Peptides, and Recombinant Proteins                                                   
  MitoTracker Deep Red FM                           ThermoFisher Scientific                       Cat\#M22426
  CM-H2DCFDA                                        ThermoFisher Scientific                       Cat\#C6827
  2-NBDG                                            Caymen Chemicals                              11046
  Fixable Live/Dead Stain Blue                      Invitrogen/ ThermoFisher Molecular Probes     Cat\#L34962; Lot\#2103470
  ACK lysing buffer                                 Thermo Scientific                             A1049201
  MitoTracker Green FM                              ThermoFisher Scientific                       Cat\#M7514
  MitoSOX Red                                       ThermoFisher Scientific                       Cat\#M36008
  Power SYBR Green Master Mix                       Applied Biosystems, ThermoFisher Scientific   Cat\#4367659
  Euk134                                            Santa Cruz                                    Cat\#sc-205321
  N-acetylcysteine amide                            Sigma                                         Cat\#A0737-5MG
  Critical Commercial Assays                                                                      
  Mouse IgG ELISpot plus kit                        MABTECH                                       Cat\#3825-2HW-plus
  Murine CD138 isolation kit                        Miltenyi Biotech                              Cat\#130-092-530
  EasySep Mouse T cell isolation kit                STEMCELL Technologies                         Cat3319851
  RNeasy mini kit                                   QIAGEN                                        Cat\#74104
  Qubit dsDNA HS Assay Kit                          Invitrogen, ThermoFisher Scientific           Cat\#Q32854
  Deposited Data                                                                                  
  RNaseq                                            [@R19]                                        NCBI GEO: GSE89511
  Microarray                                        [@R22]                                        NCBI GEO: GSE26408
  Microarray                                        [@R3]                                         NCBI GEO: GSE70294
  Experimental Models: Cell Lines                                                                 
  J558                                              ATCC                                          Cat\#TIB6; RRID: CVCL_3529
  MM.1S                                             ATCC                                          Cat\#CRL-2975; RRID: CVCL_8792
  XXO                                               ATCC                                          Cat\#TIB-20; RRID: CVCL_4696
  Experimental Models: Organisms/Strains                                                          
  Mouse: B6.129X1-*Cd28^tm2.1Jmg^*/Mmjax            Jackson                                       Stock 012305, 32040-JAX
  Mouse: C57BL/6NCrl                                Charles River                                 Strain Code 027
  Mouse: B6.129X1-*Cd28^tm1Jmg^*/Mmjax "CD28AYAA"   Jackson                                       Stock 012302, 32039-JAX
  Oligonucleotides                                                                                
  *Irf4* Forward: AGATTCCAGGTGACTCTGTG              IDT                                           N/A
  *Irf4* Reverse: CTGCCCTGTCAGAGTATTTC              IDT                                           N/A
  *actin* Forward: TACCCAGGCATTGCTGACAGG            IDT                                           N/A
  *actin* Reverse: ACTTGCGGTGCACGATGGA              IDT                                           N/A
  Software and Algorithms                                                                         
  FlowJo 10.4.1                                     FlowJo                                        <https://www.flowjo.com/solutions/flowjo/downloads>
  Prism 7                                           Graphpad                                      <https://www.graph-pad.com/scientificsoftware/prism/>

###### Highlights

-   CD28 specifically induces LLPC survival through the adaptor protein SLP76

-   CD28 activation induces ROS production, required for CD28-mediated LLPC survival

-   CD28 signaling increases LLPC glucose uptake, mitochondrial mass for metabolic fitness

-   CD28 activation increases LLPC metabolic fitness through increased IRF4 expression
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